Free Trial
NASDAQ:TRVI

Trevi Therapeutics (TRVI) Stock Price, News & Analysis

$2.50
-0.04 (-1.57%)
(As of 05/24/2024 ET)
Today's Range
$2.42
$2.58
50-Day Range
$2.50
$3.70
52-Week Range
$0.97
$4.00
Volume
431,990 shs
Average Volume
117,115 shs
Market Capitalization
$176.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Trevi Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
240.0% Upside
$8.50 Price Target
Short Interest
Healthy
1.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Trevi Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$96,366 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.42) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.59 out of 5 stars

Medical Sector

386th out of 917 stocks

Pharmaceutical Preparations Industry

169th out of 425 stocks

TRVI stock logo

About Trevi Therapeutics Stock (NASDAQ:TRVI)

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

TRVI Stock Price History

TRVI Stock News Headlines

Q1 2024 Trevi Therapeutics Inc Earnings Call
Trevi Therapeutics: Q4 Earnings Insights
See More Headlines
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
5/25/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TRVI
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$9.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+240.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-29,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.03 per share

Miscellaneous

Free Float
53,270,000
Market Cap
$176.09 million
Optionable
Optionable
Beta
0.91
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Jennifer L. Good (Age 59)
    Co-Founder, CEO, President & Director
    Comp: $781.85k
  • Dr. Thomas R. Sciascia M.D. (Age 71)
    Co-Founder & Chief Science Officer
    Comp: $530.48k
  • Dr. David J. Clark A.F.P.M. (Age 59)
    M.D., M.R.C.P., Chief Medical Officer
    Comp: $325.39k
  • Ms. Lisa Delfini (Age 54)
    Chief Financial Officer
  • Mr. Christopher Galletta (Age 46)
    Controller & Chief Accounting Officer
  • Katie McManus
    Communications Manager
  • Mr. Farrell Simon Pharm.D.
    Chief Commercial Officer
  • Ms. Danine Summers (Age 66)
    Vice President of Medical Affairs

TRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Trevi Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings
or view top-rated stocks.

What is Trevi Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 12-month target prices for Trevi Therapeutics' stock. Their TRVI share price targets range from $8.00 to $9.00. On average, they expect the company's share price to reach $8.50 in the next year. This suggests a possible upside of 240.0% from the stock's current price.
View analysts price targets for TRVI
or view top-rated stocks among Wall Street analysts.

How have TRVI shares performed in 2024?

Trevi Therapeutics' stock was trading at $1.34 at the beginning of the year. Since then, TRVI shares have increased by 86.6% and is now trading at $2.50.
View the best growth stocks for 2024 here
.

When is Trevi Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our TRVI earnings forecast
.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02.

What ETF holds Trevi Therapeutics' stock?

Simplify Propel Opportunities ETF holds 200,000 shares of TRVI stock, representing 0.58% of its portfolio.

What other stocks do shareholders of Trevi Therapeutics own?
When did Trevi Therapeutics IPO?

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.27%), Rosalind Advisors Inc. (1.34%), Propel Bio Management LLC (0.37%), Oppenheimer & Co. Inc. (0.09%), BNP Paribas Financial Markets (0.03%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Jennifer L Good, Lisa Delfini, Paul Edward Walker and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRVI) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners